Status:
UNKNOWN
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
Lead Sponsor:
Guangxi Medical University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially th...
Eligibility Criteria
Inclusion
- Age 18-75 years;
- Patients with resectable primary hepatocellular carcinoma and Cheng's type I portal vein tumor thrombus;
- Child-Pugh A or B (7 score) liver function;
- With more than 3 months expected survival;
- The volume of residual liver more than 30%;
- Patients agree to take part in.
Exclusion
- Patients with primary hepatocellular carcinoma and Cheng's type II/III/IV portal vein tumor thrombus
- Previous history of epigastric radiotherapy
- With extrahepatic metastasis
- With radiotherapy contraindication;
- Pregnant woman or sucking period;
- With repture tumor;
- With other cancer in previous five years;
- With chemothrapy, target therapy or immunosuppressive drugs therapy.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT04025437
Start Date
March 1 2019
End Date
December 31 2021
Last Update
September 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University
Nanning, Guangxi, China, 530021